What Bio-Techne's 8-K filings say: 5 filings, latest Sep 23, 2026
Bio-Techne filed its latest 8-K with the SEC on Sep 23, 2026. It discusses acquisition announced, customer churn and restructuring.
Public (TECH)Biotechnology Research1,001 to 5,000 employeesbio-techne.comLinkedIn
- Filed
- Sep 23, 2026
- Filings
- 5
- Signals
- 14
8-K · latest 8
What Bio-Techne's 8-K filings say
- SEC EDGAR
8-K
Filed · 4 signals
Bio-Techne shareholders approve acquisition by Merck KGaA, Darmstadt, Germany
Shareholder approval moves the acquisition by Merck KGaA closer to completion, intensifying the need for operational and IT integration.
The approved merger necessitates the full integration of Bio-Techne's operations into Merck KGaA.
Bio-Techne flags risk of customer loss and business disruption following merger approval.
The company explicitly identifies potential customer loss and disruption to client and supplier relationships as a key risk of the pending merger with Merck KGaA.
Merck KGaA, Darmstadt, Germany
- SEC EDGAR
8-K
Filed · 3 signals
Bio-Techne faces shareholder lawsuit over its pending acquisition by Merck KGaA, Darmstadt, Germany.
Bio-Techne is being acquired by Merck KGaA, creating significant integration needs for systems, data, and personnel.
Goldman Sachs & Co. LLCGuggenheim Securities, LLCJ.P. Morgan Securities LLC
- SEC EDGAR
8-K
Filed · 1 signal
Bio-Techne to be acquired by Merck KGaA and become a wholly-owned subsidiary.
This change of control event subordinates Bio-Techne's strategy and leadership to its new parent, Merck KGaA.
- SEC EDGAR
8-K
Filed · 3 signals
Bio-Techne to be acquired by Merck KGaA, triggering major operational integration and restructuring.
The acquisition by Merck KGaA will force a complete integration of Bio-Techne's operations, systems, and personnel.
Bio-Techne announces definitive merger agreement to be acquired by Merck KGaA, Darmstadt, Germany.
This acquisition will trigger significant operational integration, system consolidation, and budget reviews across both organizations.
- SEC EDGAR
8-K
Filed · 3 signals
The appointment of a new divisional president, following the termination of his predecessor, signals a potential strategic shift and budget review for the Diagnostics and Spatial Biology segment.
$0.5M
New President's annual base salary
75%
New President's target annual cash incentive bonus as a percentage of base salary
Thermo Fisher Scientific
Showing 8 of 14 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Bio-Techne with the Signal API
One POST /v1/companies/enrich call with bio-techne.com returns Bio-Techne 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Bio-Techne 8-K
When did Bio-Techne file its latest 8-K?
What did Bio-Techne disclose in its latest 8-K?
Where can I read Bio-Techne's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .